share_log
Reuters ·  May 1 06:33
Kalvista Pharmaceuticals: Intend to Reduce Spending on Discovery & Preclinical Activities by More Than 75%, to Less Than $5 Mln per Year
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment